1. The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada. (1st January 2021) Authors: Hu, Yannan; Charaan, Majed; van Oostrum, Ilse; Heeg, Bart; Bell, Timothy Journal: Journal of medical economics Issue: Volume 24:Number 1(2021) Page Start: 150 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗